Fractyl Health

fractyl.com →

+1%

est. 2Y upside i

HealthcareIPO

Rank

#3911

Sector

Biotechnology / Metabolic Therapeutics

Est. Liquidity

~2Y

Data Quality

Data: Medium

Fractyl Health presents a highly speculative equity opportunity for a job seeker due to an extremely severe preference stack.

Last updated: March 10, 2026

Bull (10%)+100%

Successful Revita commercialization in the post-GLP-1 weight maintenance market and positive Rejuva gene therapy data drive a significant market re-rating, pushing the company's valuation to $140M. However, with $511M in liquidation preferences, common shareholders would still likely see no return, as the valuation remains far below the total capital raised.

Base (45%)+20%

Revita gains some traction in Germany and progresses through U.S. regulatory pathways, but faces intense competition from GLP-1 drugs and other weight management strategies. The company's valuation modestly increases to $84M, but common shareholders would still realize no value due to the substantial liquidation preferences.

Bear (45%)-40%

Revita struggles with market adoption, faces unexpected regulatory delays, or fails to demonstrate sufficient differentiation against dominant GLP-1 incumbents. Further capital raises at depressed valuations or continued net losses lead to a valuation decline to $42M, resulting in a complete loss of value for common shareholders.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

67%

Investors hold approximately $511M in liquidation preferences, significantly exceeding the current market capitalization of ~$70M. This means common shareholders would likely receive nothing in an exit at or below the current valuation.

Dilution Risk

high

As a clinical-stage company with high capital intensity and ongoing losses, Fractyl Health will likely require further capital raises, leading to potential future dilution for existing shareholders.

Secondary Liquidity

active

As a publicly traded company on Nasdaq (GUTS), shares can be bought and sold on the open market, providing immediate liquidity for vested equity.

Questions to Ask at the Interview

Strategic questions based on Fractyl Health's data — designed to show you've done your homework.

  • 1

    “Given the strong market position of GLP-1 agonists like Ozempic and Wegovy, how does Fractyl Health plan to effectively differentiate Revita and capture market share in the post-GLP-1 weight maintenance segment?”

  • 2

    “With current revenue being minimal and significant net losses, what is the long-term commercialization strategy for Revita, particularly regarding reimbursement and scaling operations beyond the pilot launch in Germany?”

  • 3

    “Considering the substantial amount of capital raised ($511M) relative to the current market capitalization (~$70M), what is the company's strategy to create meaningful value for common shareholders over a 2-year horizon?”

Community

Valuation Sentiment

Our model estimates +1% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.